We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Allena Pharmaceuticals Inc | NASDAQ:ALNA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.075 | 0.0825 | 0.0832 | 0 | 01:00:00 |
As filed with the Securities and Exchange Commission on March 11, 2021
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
ALLENA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 45-2729920 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. employer identification no.) |
One Newton Executive Park, Suite 202
Newton, Massachusetts 02462
(Address of principal executive offices)
Allena Pharmaceuticals, Inc. 2017 Stock Option and Incentive Plan
(Full title of the plan)
Louis Brenner
Chief Executive Officer and President
Allena Pharmaceuticals, Inc.
One Newton Executive Park, Suite 202
Newton, Massachusetts 02462
(Name and address of agent for service)
(617) 467-4577
(Telephone Number, Including area code, of Agent for Service)
Copy to:
Michael H. Bison
Daniel Lang
Goodwin Procter LLP
100 Northern Avenue
Boston, Massachusetts 02210
(617) 570-1000
Fax: (617) 523-1231
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company |
☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
CALCULATION OF REGISTRATION FEE
|
||||||||
Title of securities to be registered |
Amount to be Registered (1) |
Proposed maximum offering price per share (2) |
Proposed maximum aggregate offering price |
Amount of registration Fee |
||||
Common Stock (par value $0.001) |
2,032,854 shares (3) | $1.42 | $2,886,652.68 | $314.94 | ||||
|
||||||||
|
(1) |
Pursuant to Rule 416 under the Securities Act of 1933, as amended (the Securities Act), this registration statement shall also cover any additional shares of common stock which become issuable under the Registrants 2017 Stock Option and Incentive Plan (the Plan) by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock. |
(2) |
Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(h) of the Securities Act, and based on the average of the high and low sale prices of the Registrants Common Stock, as quoted on the Nasdaq Global Select Market, on March 5, 2021. |
(3) |
Represents an automatic increase to the number of shares of Common Stock to the number of shares available for issuance under the Plan, effective January 1, 2021. Shares available for issuance under the Plan were previously registered on registration statements on Form S-8 filed with the Securities and Exchange Commission on March 16, 2020 (Registration No. 333-237218), March 7, 2019 (Registration No. 333-230127), March 27, 2018 (Registration No. 333-223939) and November 2, 2017 (Registration No. 333-221306). |
EXPLANATORY NOTE
This Registration Statement on Form S-8 registers additional shares of Common Stock under the Registrants 2017 Stock Option and Incentive Plan (the Plan). The number of shares of Common Stock reserved and available for issuance under the Plan is subject to an automatic annual increase on each January 1, beginning in 2018, by an amount equal to four percent of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31 or such lesser number of shares of Common Stock as determined by the Administrator (as defined in the Plan). Accordingly, on January 1, 2021, the number of shares of Common Stock reserved and available for issuance under the Plan increased by 2,032,854 shares. This Registration Statement registers these additional 2,032,854 shares of Common Stock. The additional shares are of the same class as other securities relating to the above referenced plans for which the Registrants registration statements filed on Form S-8 on March 16, 2020 (Registration No. 333-237218), March 7, 2019 (Registration No. 333-230127), March 27, 2018 (Registration No. 333-223939) and November 2, 2017 (Registration No. 333-221306) are effective. The information contained in the Registrants registration statements on Form S-8 (Registration No. 333-230127, Registration No. 333-223939 and Registration No. 333-221306) are hereby incorporated by reference pursuant to General Instruction E.
Part II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits
(1) |
Filed as Exhibit 3.1 to the Registrants Form 8-K, filed previously with the Commission on November 6, 2017 and incorporated by reference herein. |
(2) |
Filed as Exhibit 3.2 to the Registrants Form 8-K, filed previously with the Commission on November 6, 2017 and incorporated by reference herein. |
(3) |
Filed as Exhibit 4.1 to the Registrants Registration Statement on Form S-1, as amended (File No. 333-220857), filed previously with the Commission on October 23, 2017 and incorporated by reference herein. |
(4) |
Filed as Exhibit 4.2 to the Registrants Registration Statement on Form S-1 (File No. 333-220857), filed previously with the Commission on October 6, 2017 and incorporated by reference herein. |
(5) |
Filed as Exhibit 4.3 to the Registrants Registration Statement on Form S-1 (File No. 333-220857), filed previously with the Commission on October 6, 2017 and incorporated by reference herein. |
(6) |
Filed as Exhibit 4.4 to the Registrants Registration Statement on Form S-1 (File No. 333-220857) filed previously with the Commission on October 6, 2017 and incorporated by reference herein. |
(7) |
Filed as Exhibit 4.1 to the Registrants Form 8-K, filed previously with the Commission on October 1, 2020 and incorporated by reference herein. |
(8) |
Filed as Exhibit 10.2 to the Registrants Registration Statement on Form S-1, as amended (File No. 333-220857), filed previously with the Commission on October 23, 2017 and incorporated by reference herein. |
* |
Filed herewith. |
Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Newton, Commonwealth of Massachusetts, on March 11, 2021.
ALLENA PHARMACEUTICALS, INC. | ||
By: |
/s/ Louis Brenner |
|
Louis Brenner, M.D. | ||
Chief Executive Officer and President |
POWER OF ATTORNEY
We, the undersigned officers and directors of Allena Pharmaceuticals, Inc., hereby severally constitute and appoint Louis Brenner, M.D. and Richard Katz, M.D., and each of them singly, our true and lawful attorneys, with full power to sign for us in our names in the capacities indicated below, any amendments to this Registration Statement on Form S-8 (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, and generally to do all things in our names and on our behalf in our capacities as officers and directors to enable Allena Pharmaceuticals, Inc., to comply with the provisions of the Securities Act of 1933, as amended, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and all amendments thereto.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities indicated and on the date indicated.
Name |
Title |
Date |
||
/s/ Louis Brenner Louis Brenner, M.D. |
President, Chief Executive Officer and Director (Principal Executive Officer) |
March 11, 2021 | ||
/s/ Richard Katz Richard Katz, M.D. |
Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |
March 11, 2021 | ||
/s/ Alexey Margolin Alexey Margolin, Ph.D. |
Director | March 11, 2021 | ||
/s/ Allene Diaz Allene Diaz |
Director | March 11, 2021 | ||
/s/ Andrew A. F. Hack |
Director | March 11, 2021 | ||
Andrew A. F. Hack, M.D., Ph.D. | ||||
/s/ Gino Santini Gino Santini |
Director | March 11, 2021 | ||
/s/ Ann C. Miller Ann C. Miller, M.D. |
Director | March 11, 2021 | ||
/s/ James N. Topper, M.D., Ph.D. James N. Topper, M.D., Ph.D. |
Director | March 11, 2021 | ||
/s/ Robert Alexander, Ph.D. Robert Alexander, Ph.D. |
Director | March 11, 2021 |
1 Year Allena Pharmaceuticals Chart |
1 Month Allena Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions